Serina Therapeutics Inc Statistics
Share Statistics
Serina Therapeutics Inc has 8.89M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 8.89M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 5.40K |
| FTD / Avg. Volume | 21.61% |
Short Selling Information
The latest short interest is 35.94K, so 0.4% of the outstanding shares have been sold short.
| Short Interest | 35.94K |
| Short % of Shares Out | 0.4% |
| Short % of Float | 1.19% |
| Short Ratio (days to cover) | 1.21 |
Valuation Ratios
The PE ratio is -1 and the forward PE ratio is null.
| PE Ratio | -1 |
| Forward PE | null |
| PS Ratio | 104.48 |
| Forward PS | null |
| PB Ratio | 2.71 |
| P/FCF Ratio | -1.9 |
| PEG Ratio | n/a |
Enterprise Valuation
Serina Therapeutics Inc has an Enterprise Value (EV) of 18.36M.
| EV / Earnings | -1.24 |
| EV / Sales | 129.3 |
| EV / EBITDA | -1.88 |
| EV / EBIT | -1.84 |
| EV / FCF | -2.35 |
Financial Position
The company has a current ratio of 0.13, with a Debt / Equity ratio of 0.8.
| Current Ratio | 0.13 |
| Quick Ratio | 0.13 |
| Debt / Equity | 0.8 |
| Total Debt / Capitalization | 44.39 |
| Cash Flow / Debt | -1.79 |
| Interest Coverage | -2.03 |
Financial Efficiency
Return on equity (ROE) is -2.71% and return on capital (ROIC) is -102.38%.
| Return on Equity (ROE) | -2.71% |
| Return on Assets (ROA) | -1.24% |
| Return on Capital (ROIC) | -102.38% |
| Revenue Per Employee | 15.78K |
| Profits Per Employee | -1.64M |
| Employee Count | 9 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -8.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -63.78% in the last 52 weeks. The beta is 0, so Serina Therapeutics Inc's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -63.78% |
| 50-Day Moving Average | 5.4 |
| 200-Day Moving Average | 7.99 |
| Relative Strength Index (RSI) | 43.98 |
| Average Volume (20 Days) | 24.98K |
Income Statement
In the last 12 months, Serina Therapeutics Inc had revenue of 142.00K and earned -14.80M in profits. Earnings per share was -13.72.
| Revenue | 142.00K |
| Gross Profit | -29.00K |
| Operating Income | -9.96M |
| Net Income | -14.80M |
| EBITDA | -9.78M |
| EBIT | -9.96M |
| Earnings Per Share (EPS) | -13.72 |
Balance Sheet
The company has 345.00K in cash and 4.37M in debt, giving a net cash position of -4.02M.
| Cash & Cash Equivalents | 345.00K |
| Total Debt | 4.37M |
| Net Cash | -4.02M |
| Retained Earnings | -131.01M |
| Total Assets | 7.43M |
| Working Capital | -8.09M |
Cash Flow
In the last 12 months, operating cash flow was -7.80M and capital expenditures 0, giving a free cash flow of -7.80M.
| Operating Cash Flow | -7.80M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.80M |
| FCF Per Share | -7.23 |
Margins
Gross margin is -2.04K%, with operating and profit margins of -701.41K% and -1.04M%.
| Gross Margin | -2.04K% |
| Operating Margin | -701.41K% |
| Pretax Margin | -1.04M% |
| Profit Margin | -1.04M% |
| EBITDA Margin | -6.89K% |
| EBIT Margin | -7.01K% |
| FCF Margin | -5.49K% |
Dividends & Yields
SER does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -282.89% |
| FCF Yield | -18.09% |
Analyst Forecast
Currently there are no analyst rating for SER.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 15, 2024. It was a backward split with a ratio of 7:250.
| Last Split Date | Mar 15, 2024 |
| Split Type | backward |
| Split Ratio | 7:250 |
Scores
| Altman Z-Score | -6.78 |
| Piotroski F-Score | 2 |